In Q3 2026, TRON recorded $2.21 trillion in stablecoin settlements and $701.4 million in network fees, reflecting stablecoin movements and blockchain resource costs, not direct revenue. The number of transactions remained steady at about 1.10 billion, indicating higher value per transfer or different transaction types. Network fees arise from resource use like bandwidth and energy, paid via staking or token burns, and are not distributed as direct income to TRON DAO or token holders. Future monitoring of transaction counts, fee structures, and resource parameters will clarify TRON's economic impact and fee dynamics.
TRON's stablecoin transfers reached $2.21 trillion in Q3 2026, with $701.4 million in network fees and about 1.10 billion transactions. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 17:02 WIB: 33 of 50 major cryptocurrencies rose, 16 fell. Notable movers include SAND at Rp1.055 (-5.15%), CRV at Rp6.308 (+3.56%), and BCH at Rp5.046.325 (+2.75%).
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
